Rosiglitazone reduces urinary albumin excretion in type II diabetes.
about
Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusRosiglitazone for type 2 diabetes mellitusL2L: a simple tool for discovering the hidden significance in microarray expression dataNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Improvements in the Management of Diabetic NephropathyDiabetic cardiomyopathy: signaling defects and therapeutic approachesPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic ratsAre thiazolidinediones good or bad for the heart?Management of type 2 diabetes mellitus. Role of thiazolidinediones.Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR.Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspectiveOral antihyperglycemic therapy for type 2 diabetes mellitus.Prolonged induction activates Cebpα independent adipogenesis in NIH/3T3 cells.Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification.Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.Comparative effectiveness of incident oral antidiabetic drugs on kidney functionPleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.Diabetic cardiomyopathy: is resistin a culprit?Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease.Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.Emerging drugs for diabetic nephropathy.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.Thiazolidinediones and diabetic nephropathy: need for a closer examination?Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF ratsPPARs and the kidney in metabolic syndrome.
P2860
Q24186660-76EE62D5-EC83-45AA-B0E6-A97D58CE53D6Q24197884-EB334E32-A36A-4E4E-82BC-2893B57BEAD8Q24243875-8C50F02F-1F0D-4CEF-AE89-A41C97E691DFQ24814110-175729A3-D587-4F5E-9520-CAD74160143FQ26777994-B6F88ACC-9701-49DC-B0FE-C50AF7420E36Q28080717-C9F683FD-9FFF-48B5-94CF-0487F290961EQ28395852-CB1DCDFF-8412-48C5-A36F-1FDE14D5F49FQ28580246-9061A0F8-4314-43EE-A95D-5AB4FD55B95FQ30435005-76D24E14-01C1-4E3C-8ADF-C5169A18C0F5Q33216408-A7365151-F521-4C3B-835D-6AD85651EAA9Q33413024-221B1C65-C154-4E0B-BE24-60DF55711885Q33440398-AC49FC93-03F3-4118-B3AB-C1E3F0294BC5Q33587783-2E7CDE16-7F8B-4A31-BF98-D11E6224B86AQ33713451-29BBA146-9D5A-4548-984A-565BB770F40FQ34550865-3F3F684A-6779-4E68-A697-79B5A51AFA3AQ34926845-93EA7CAB-D865-4B80-ADB6-A7CA10FB1989Q34998284-3535DEA6-FD67-4DCB-A732-2FD4FCBFADBBQ35061696-49E41F72-6D60-41DF-A3EF-2C02BC3D6014Q35161366-157A6639-8348-4F5A-A744-D55154FEB046Q35588998-5D0B9EC1-5957-4AA4-9152-BBBE4973C3D0Q35688221-37083CC6-797F-4676-A66B-D50315E3070BQ35784092-F9BA376B-F71C-4DD7-A7EC-004574E6C42EQ35835288-440B8EB3-5A52-4A2A-948C-8BB557B8D3B6Q36068458-120F6E0E-C296-42F1-BAA8-33D4736E9CE7Q36174452-94E4B073-4854-4DE5-918D-8CE195F35AB7Q36196571-E2FE2A7E-06B5-45E7-B7B4-3F77B867900CQ36262404-496F9FA7-C4C6-4876-9175-BE6F6606E76BQ36283822-D4940D7E-8543-4639-9DD4-3AE1A2FB8D62Q36302838-B7967188-31CA-4F89-BEA0-C98143B4882EQ36319330-ED9305AF-3A93-4383-8480-4DDA68FC1BCAQ36390892-603FBAF8-F1C9-495E-80DE-5F3BE77F19F2Q36507641-F6F8551A-9E11-4CA5-8B97-9DD3D5900B6BQ36577073-F627C8C7-844C-457A-9B91-DA8A69B1DAC8Q36679594-5C72FD6C-7237-456D-8FED-F22B44218269Q36835841-43B91F2C-4493-4957-A0AD-463A91BDBE2FQ36877514-30D630A4-C952-4D6A-9B68-F3DD695643ACQ37024419-E92A8CCE-2BE9-43C4-B0F1-4DEAE4B2E2E2Q37042128-800318B7-8AAA-4EA2-8079-D4A70D058327Q37065532-E5DC3088-F4F5-4444-AF3D-7A25B08610F6Q37072216-98D1BABD-F0A1-4CF7-8A87-1D0DA81E6B80
P2860
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@en
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@nl
type
label
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@en
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@nl
prefLabel
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@en
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@nl
P2093
P2860
P356
P1476
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
@en
P2093
P2860
P2888
P356
10.1038/SJ.JHH.1001444
P577
2003-01-01T00:00:00Z